Victoria's Secret stock soars nearly 300% as GLP-1 weight-loss drugs help reshape lingerie buying habits

Victoria's Secret shares have skyrocketed nearly 300% over the past year, trading under the ticker VSXY since June 2026. The surge in stock price has been attributed to stronger sales, a revamped brand strategy, and a new management team. However, analysts are also suggesting that GLP-1 weight-loss drugs, like Ozempic, Wegovy, and Zepbound, are playing an unexpected role in the company's turnaround.

As millions of people using these medications lose weight, they may need to replace their clothing, driving a potential spending boom for lingerie retailers like Victoria's Secret. The company's CEO, Hillary Super, noted a 3% decrease in bra-band and underwear sizes purchased, attributing it to weight loss. Additionally, research suggests that losing weight can increase feelings of sexual attractiveness, further boosting demand for intimate apparel.

Victoria's Secret has also reported stronger financial results under Super's leadership, with sales up 15% and operating income jumping to $76 million. While GLP-1s alone haven't driven the recent share price increase, they are contributing to the company's overall growth and success.